BridgeBio Pharma, Inc. BBIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:05 PM ET
- YTD
- -2.01%
- 1 year
- +18.27%
- Open
- 72.85
- Prev close
- 70.73
- Mkt cap
- 14.65B
- Vol
- 5.77M
- Avg vol
- 2.52M
- EPS
- -3.56
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 71.91
- High
- 75.65
- Forward P/E
- -333.67
- Beta
- 0.97
- Short ratio
- 6.50
- Inst. own
- 99.55%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 70.43
- 200-d avg
- 72.76
- 1y target
- 107.81
5D chart
Events in this range
- Oct 29, 2026Earnings: -0.42; estimate -0.54225; surprise 22.54%
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
Signals (115)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 1:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:50 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:10 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:55 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:10 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:55 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| RSI: Overbought | Oct 28, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
-
1 day ago benzinga.com
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.
-
1 day ago benzinga.com
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.
2 days ago seekingalpha.com
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
2 days ago marketbeat.com
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
BridgeBio Pharma NASDAQ: BBIO reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's…
2 days ago zacks.com
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
2 days ago zacks.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.95 per share a year ago.
2 days ago benzinga.com
BridgeBio Pharma Q3 2026 Earnings Call Transcript
BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
2 days ago benzinga.com
BridgeBio Pharma Q3 2026 Earnings Call Transcript
BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
2 days ago globenewswire.com
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over…
-
1 week ago benzinga.com
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.
-
1 week ago benzinga.com
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.
-
1 week ago benzinga.com
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.
-
2 weeks ago benzinga.com
Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in…
-
2 weeks ago benzinga.com
Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156
Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.
-
3 weeks ago benzinga.com
BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today…
-
3 weeks ago benzinga.com
Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima
- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12…